Weed Killer Proves Beneficial For Rare Liver Disease

Article

WASHINGTON, DC-Parents of children born with tyrosinemia were warned that those inflicted with the hereditary disease have a 29% survival rate. The rare liver disease prevents the body from properly breaking down specific amino acids.

However, a rare solution may help fight the rare disease. Researchers at Sweden's Gothenberg University noticed a failed herbicide, produced by Zeneca Inc., broke down the same amino acid compounds. The drug Orfadin was created from the failed weed killer, and patented by a mall Nashville-based pharmaceutical company-Rare Disease Therapeutics.

Hereditary tyrosinemia type 1 causes progressive liver failure and liver cancer in young children. Yet in Orfadin studies, 89% of those inflicted lived four years or more. The drug blocks specific liver-destroying proteins. Previous treatments centered on no-protein diets, but were rarely successful.

The drug will cost $12,000 per year for infants, but Rare Disease Therapeutic vice president Bo Allen has said no child will be turned away from treatment.

The company received a special seven-year patent on the drug through an FDA program for rare diseases.

There are an estimated 100 children with the disease.

Information from www.msnbc.com

Recent Videos
Hannah Schroeder, BSHA, CRCST, CIS, CHL, CER,
Anthony Bondon CRCST, CHL, BSM, AAS, SME, LSSYB
Deannard Esnard, CRCST, CIS, CER, CHL, CFER, CQUIA
Kevin Bush, Jr, DHSc, EdD, MSHA, MA, MS, FACHE
Vatsala Rangachar Srinivasa, MPH
Sarah Vinson, MBA, CRCST
Kevin Anderson, MBA, BS, CRCST, Senior Manager, Commercial Education Services, Heatlthmark, a Getinge Company
Damien Berg, BA, BS, CRCST, AAMIF, is the vice president of strategic initiatives for the HSPA.
Annet Adegboyega, DNP, MSN, BSN, RN, CNOR; Mihyun "Rose" Jang, MSN, MPH, BSN, RN, CNOR; and Renilda Tijones, MSN, BSN, RN, CNOR.
Roundtable of Vet IPs (Adobe Stock)
Related Content